These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9597898)

  • 1. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
    Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
    Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia].
    Ikeda K; Mita M; Ishibashi T; Shichishima T; Maruyama Y
    Rinsho Ketsueki; 1998 Sep; 39(9):676-9. PubMed ID: 9796402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in therapy for chronic myelogenous leukemia].
    Urabe A
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
    Buesche G; Hehlmann R; Hecker H; Heimpel H; Heinze B; Schmeil A; Pfirrmann M; Gomez G; Tobler A; Herrmann H; Kappler M; Hasford J; Buhr T; Kreipe HH; Georgii A
    Leukemia; 2003 Dec; 17(12):2444-53. PubMed ID: 14562117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
    Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [One-year remission of chronic myelogenous leukemia (CML) after discontinuation of interferon-alpha].
    Kobayashi Y; Kimura S; Tanaka K; Kimura S; Wada K; Ozawa M; Maruo N; Kondo M
    Rinsho Ketsueki; 1990 Jul; 31(7):1013-6. PubMed ID: 2214181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma].
    Hasegawa A; Ninomiya H; Yanagisawa K; Takada K; Hasegawa H; Hato T; Yasukawa M; Fujita S
    Rinsho Ketsueki; 1996 Sep; 37(9):853-7. PubMed ID: 8914475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines.
    Tamura T; Matsuzaki M; Harada H; Ogawa K; Mohri H; Okubo T
    J Investig Med; 1997 Apr; 45(4):160-7. PubMed ID: 9154296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anhidrosis during long-term hydroxyurea therapy in a patient with chronic myelogenous leukemia].
    Takagi K; Nakamura T; Misaki H; Ueda T
    Rinsho Ketsueki; 2000 Nov; 41(11):1214-9. PubMed ID: 11193442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pure red cell aplasia occurring during the course of chronic myelogenous leukemia].
    Yasuyama M; Kawauchi K; Takei K; Ogasawara T; Ohkawa S
    Rinsho Ketsueki; 2004 Jan; 45(1):66-71. PubMed ID: 14999937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
    Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intermittent administration of natural interferon-alpha for over 5 years induced complete suppression of Philadelphia chromosome in a patient with myelogenous leukemia].
    Koyama S; Aoki S; Furukawa T; Takahashi M; Kishi K; Koike T; Moriyama Y; Hattori A; Shibata A
    Rinsho Ketsueki; 1991 Dec; 32(12):1577-9. PubMed ID: 1779460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphoid blast crisis during interferon-alpha therapy in a patient with chronic myelogenous leukemia in myeloid blast crisis.
    Goto H; Tsurumi H; Hara T; Moriwaki H
    Int J Hematol; 2000 Dec; 72(4):474-6. PubMed ID: 11197215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
    Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.